Immix Biopharma, Inc. (IMMX)
7.48
-0.36
(-4.59%)
USD |
NASDAQ |
Nov 16, 16:00
7.49
+0.01
(+0.13%)
After-Hours: 20:00
Immix Biopharma Enterprise Value : 291.58M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 291.58M |
| November 13, 2026 | 321.75M |
| November 12, 2026 | 341.03M |
| November 11, 2026 | 390.48M |
| November 10, 2026 | 364.50M |
| November 09, 2026 | 382.93M |
| November 06, 2026 | 340.19M |
| November 05, 2026 | 268.11M |
| November 04, 2026 | 332.65M |
| November 03, 2026 | 310.86M |
| November 02, 2026 | 273.14M |
| October 30, 2026 | 308.34M |
| October 29, 2026 | 333.48M |
| October 28, 2026 | 345.64M |
| October 27, 2026 | 339.35M |
| October 26, 2026 | 340.19M |
| October 23, 2026 | 347.73M |
| October 22, 2026 | 364.50M |
| October 21, 2026 | 377.91M |
| October 20, 2026 | 411.43M |
| October 19, 2026 | 353.60M |
| October 16, 2026 | 333.48M |
| October 15, 2026 | 392.15M |
| October 14, 2026 | 377.91M |
| October 13, 2026 | 392.99M |
| Date | Value |
|---|---|
| October 12, 2026 | 439.93M |
| October 09, 2026 | 457.53M |
| October 08, 2026 | 443.28M |
| October 07, 2026 | 460.04M |
| October 06, 2026 | 472.61M |
| October 05, 2026 | 513.68M |
| October 02, 2026 | 475.97M |
| October 01, 2026 | 522.06M |
| September 30, 2026 | 536.73M |
| September 29, 2026 | 522.88M |
| September 28, 2026 | 589.41M |
| September 25, 2026 | 553.64M |
| September 24, 2026 | 605.86M |
| September 23, 2026 | 621.60M |
| September 22, 2026 | 686.70M |
| September 21, 2026 | 660.94M |
| September 18, 2026 | 663.09M |
| September 17, 2026 | 678.83M |
| September 16, 2026 | 621.60M |
| September 15, 2026 | 637.34M |
| September 14, 2026 | 642.35M |
| September 11, 2026 | 637.34M |
| September 10, 2026 | 677.40M |
| September 09, 2026 | 649.50M |
| September 08, 2026 | 716.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
| Savara, Inc. | 818.43M |
| Arrowhead Pharmaceuticals, Inc. | 6.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.93M |
| Total Expenses (Quarterly) | 13.93M |
| EPS Diluted (Quarterly) | -0.188 |
| Earnings Yield | -11.10% |
| Normalized Earnings Yield | -11.10 |